Feature Image

Marijuana Compound May Beat Antipsychotics at Treating Schizophrenia

cannabidiol (CBD), the key cannabinoid component in dozens of Medical Marijuana, Inc. portfolio products. The University of Cologne in Germany conducted a study on the effectiveness of CBD versus standard anti-psychotics. PsychCentral.com outlines the results of this groundgreaking CBD-only treatment for schizophrenia patients. From the article:

  • “The results were amazing,” said Daniel Piomelli, Ph.D., professor of pharmacology at the University of California-Irvine and a co-author of the study. “Not only was [CBD] as effective as standard antipsychotics, but it was also essentially free of the typical side effects seen with antipsychotic drugs.”
Click here to read the full breakthrough article on PsychCentral.com. We are working tirelessly to make natural CBD available to consumers and researchers. Our CBD is derived from industrial hemp—not marijuana—which why our CBD-rich hemp oil and related products are legal to purchase in the US. Learn more about CBD here.]]>

Post by Jeffrey Stamberger

Jeffrey writes media content covering the latest in news, medical research, policy changes, and product education from the cannabis industry.

View More